Selexis SA, a JSR Life Science Company, is the global leader in mammalian cell line development with best-in-class modular technology and highly specialized solutions that enable the life science industry to rapidly develop and commercialize innovative biotherapeutics and vaccines.
USING INNOVATION TO DE-RISK AND ACCELERATE THE DISCOVERY AND DEVELOPMENT OF NEW THERAPEUTICS
JSR Life Sciences brings together the best-in-class capabilities of its affiliates, deep biochemical knowledge and understanding of human disease biology, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for its customers.
In 2022, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.
For more than 20 years, Selexis has helped its partners predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology Platform™ is being used by global partners, resulting in nearly 150 biologic drug candidates in clinical development and nine products in commercial manufacturing. Selexis is able to generate stable and high-expressing (up to 10 g/L in bioreactor*) research cell banks (RCBs) in as little as 8–12 weeks.
At Selexis, diversity, inclusion, and equality have been a part of our DNA since our founding. Having varied perspectives drives innovation, impacts our products and services, and helps us better serve our partners and employees. While we have more work to do to advance diversity and inclusion, we are constantly growing, learning, and iterating to move our company forward.
The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors. Therapeutics that have been generated using Selexis SURE CHO-M cells include more than 140 clinical trial, as well as 8 marketed products across a range of indications.
Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.
Trust develops when credibility, respect and fairness thrive in a workplace. A culture of trust gives rise to camaraderie and pride. The survey uses 58 closed questions in the Trust-Index employee survey to find out how employees see the following dimensions in their company….
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.
